Financing, Special Reports, and Clinical Trial Updates - Research Report on PDL, DexCom, Quintiles, KYTHERA, and Nektar PR Newswire NEW YORK, November 20, 2013 NEW YORK, November 20, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting PDL BioPharma, Inc. (NASDAQ: PDLI), DexCom, Inc. (NASDAQ: DXCM), Quintiles Transnational Holdings, Inc. (NYSE: Q), KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH), and Nektar Therapeutics (NASDAQ: NKTR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. PDL BioPharma, Inc. Research Report On November 6, 2013, PDL BioPharma, Inc. (PDL) announced that it has closed a financing transaction with Durata Therapeutics, Inc. (Durata).Under the credit agreement, PDL will provide Durata with up to $70 million of debt financing with a five-year term and will receive interest on the principal amount outstanding and a security interest in substantially all of Durata's assets. "We are pleased to provide this non-dilutive financing to Durata. Based upon our extensive due diligence, we believe that dalbavancin will be a medically and commercially significant product," said John P. McLaughlin, President and CEO of PDL. "This deal with Durata marks the fourth transaction we have closed in recent weeks and, in doing so, we believe that we are securing measurable value for PDL and our stockholders." The Full Research Report on PDL BioPharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/066b_PDLI DexCom, Inc. Research Report On November 6, 2013, DexCom, Inc. (DexCom) announced that it has appointed Steve Altman as an independent Board member of the Company. According to DexCom, Altman is currently the Vice Chairman of Qualcomm Incorporated (Qualcomm) and has served on its executive committee for almost 15 years. "We are thrilled to announce Steve's addition to the Board," said Terry Gregg, CEO of DexCom. "Steve is an incredibly skilled, passionate and visionary business leader who will bring a unique and important perspective to our Board. His experience in directing Qualcomm's growth will be invaluable as we continue to design and execute our own growth strategy. We welcome Steve to our Board of Directors." The Full Research Report on DexCom, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/d377_DXCM Quintiles Transnational Holdings, Inc. Research Report On November 14, 2013, Quintiles Transnational Holdings, Inc. (Quintiles) announced that it has published its perspectives on diabetes drug development with a special report on development for pediatric indications, in relation to World Diabetes Day. The Company noted that the report addresses specific clinical, design, and operational considerations for pediatric diabetes clinical trials. According to Quintiles, the report also concludes that the disease burden is high, with a large unmet need for new diabetes therapies in the pediatric population. Further, the report provides information to assist in the planning of pediatric studies aimed at making more treatment options available to children. "Whether our sponsors grapple with the challenge of designing trials in a renally-impaired diabetic population or are creating an insulin algorithm for a type one diabetes population, they turn to Quintiles for our extensive experience in clinical research," said Erica Caveney, M.D., Senior Director and Global Diabetes Therapeutic Strategy Head of Cardiovascular and Metabolic Therapeutic Delivery Unit at Quintiles. The Full Research Report on Quintiles Transnational Holdings, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/9f5c_Q KYTHERA Biopharmaceuticals, Inc. Research Report On November 14, 2013, KYTHERA Biopharmaceuticals, Inc. (KYTHERA) reported Q3 2013 financial results. In Q3 2013, the Company recorded net loss of $11.5 million, or $0.62 loss per basic and diluted share, compared with net loss of $16.4 million, or $11.41 loss per basic and diluted share, in Q3 2012. "We are very pleased with the recent positive results from our pivotal Phase III clinical trials that demonstrate the ability of ATX-101 to reduce fat under the chin and improve the patient's submental profile. We are now focused on the preparation and filing of our New Drug Application, which we expect to occur in the second quarter of 2014," said Keith Leonard, President and CEO of KYTHERA. "We believe these positive results, coupled with our strong balance sheet as a result of our recently closed public offering, position us well to execute on our business objectives." The Full Research Report on KYTHERA Biopharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/b90a_KYTH Nektar Therapeutics Research Report On November 13, 2013, Nektar Therapeutics (Nektar) reported that Baxter International Inc. (Baxter) has completed enrollment in its Phase III clinical trial of BAX 855, an investigational extended half-life, recombinant factor VIII treatment for hemophilia A, and employs proprietary PEGylation technology from Nektar to extend duration of activity of proteins. Nektar further reported that Baxter expects to complete the trial and file for regulatory approval in late 2014. "The BAX 855 development program is a priority for Baxter as we evaluate the potential to provide an efficacious and safe treatment with an extended half-life for patients with hemophilia," said Anders Ullman, M.D., Ph.D., Vice President of Global Research and Development in Baxter's BioScience business. "We are focused first and foremost on strategies to address optimal efficacy and minimize patients' bleeding episodes, while at the same time delivering on the convenience of less frequent dosing for this population with severe disease." The Full Research Report on Nektar Therapeutics - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/3421_NKTR EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. http://www.analystscorner.com/ SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Financing, Special Reports, and Clinical Trial Updates - Research Report on PDL, DexCom, Quintiles, KYTHERA, and Nektar
Press spacebar to pause and continue. Press esc to stop.